St. Louis Trust Co Acquires 1,233 Shares of Axon Enterprise, Inc $AXON

St. Louis Trust Co increased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 80.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,757 shares of the biotechnology company’s stock after purchasing an additional 1,233 shares during the period. St. Louis Trust Co’s holdings in Axon Enterprise were worth $1,171,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AXON. Vanguard Group Inc. raised its position in shares of Axon Enterprise by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after buying an additional 53,060 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Axon Enterprise by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after acquiring an additional 35,544 shares during the last quarter. Baillie Gifford & Co. boosted its position in shares of Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after acquiring an additional 1,516,099 shares during the last quarter. Sands Capital Management LLC boosted its position in shares of Axon Enterprise by 11.6% during the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after acquiring an additional 167,095 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after acquiring an additional 1,179,038 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AXON has been the topic of a number of research reports. Citizens Jmp reiterated a “market outperform” rating and issued a $700.00 price target on shares of Axon Enterprise in a report on Thursday, June 25th. Piper Sandler increased their price objective on shares of Axon Enterprise from $674.00 to $724.00 and gave the company an “overweight” rating in a report on Monday, July 13th. The Goldman Sachs Group set a $535.00 price objective on Axon Enterprise in a research report on Thursday, May 7th. Needham & Company LLC lifted their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a report on Monday, July 6th. Finally, JPMorgan Chase & Co. lifted their target price on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Fifteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $725.25.

Insider Transactions at Axon Enterprise

In other news, CRO Cameron Brooks sold 1,242 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive directly owned 49,710 shares in the company, valued at approximately $24,855,000. This represents a 2.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. The trade was a 4.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 58,989 shares of company stock worth $30,527,983. 4.20% of the stock is currently owned by corporate insiders.

Axon Enterprise Trading Up 2.1%

Shares of AXON opened at $502.34 on Friday. The company’s fifty day moving average is $483.26 and its 200 day moving average is $479.59. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The stock has a market capitalization of $40.49 billion, a PE ratio of 201.74, a P/E/G ratio of 10.04 and a beta of 1.38. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same quarter in the prior year, the firm earned $1.47 earnings per share. Axon Enterprise’s revenue was up 33.7% on a year-over-year basis. Sell-side analysts expect that Axon Enterprise, Inc will post 1.63 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.